Does ST-Elevation MI Need a Rebrand to ‘Occlusion MI’? (The Bob Harrington Show, Medscape Cardiology, by Dr. Robert Harrington)
In this Bob Harrington Show episode from Medscape Cardiology, experts debate whether the long-standing STEMI/NSTEMI classification should shift to Occlusion MI (OMI). They argue that the focus should be on identifying and treating closed arteries early — supported by new tools like AI-driven ECGs, home monitoring, and advanced biomarkers.
About the Podcast
The Bob Harrington Show on Medscape Cardiology brings leading voices in cardiovascular medicine together to discuss evolving evidence, clinical paradigms, and future directions in patient care. Hosted by Dr. Robert Harrington, the show features thought-provoking conversations with renowned experts.
Summary of the Episode
In this episode, Dr. Harrington speaks with Dr. C. Michael Gibson (Harvard/Baim Institute) and Dr. Manesh Patel (Duke University) about the shifting paradigm from ST-Elevation MI (STEMI) to Occlusion MI (OMI).
- Relying solely on ST-segment elevation misses many patients with an occluded artery, including posterior infarcts, transient occlusions, and subtle cases.
- False alarms and delays remain challenges: ~30–40% of STEMI cath lab activations may be “false positives,” yet many of these cases still involve dynamic coronary occlusion.
- The future of acute MI diagnosis will likely combine AI-based ECG interpretation, home and wearable monitoring, and biomarker detection to catch occlusions earlier.
- Panelists emphasized the need for a clinical shift: focus less on ECG labels and more on whether an artery is closed and needs urgent reperfusion.
“It’s time to move beyond ST elevation. The real question is: is the artery closed? If so, patients need timely intervention — whether or not the ECG shows elevation.”— Dr. C. Michael Gibson, The Bob Harrington Show
🎧 Listen to the episode: Official page | Spotify | Apple Podcasts
Share this article
About PMcardio
PMcardio features CE-certified AI ECG models that interpret any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
